Defective Medicinal Products: Global Recall Process Expectations in 2026

MHRA Updates and Global Alignment for Product Recalls

Defective medicinal products are under sharper regulatory scrutiny than ever. In early 2026, the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) released an updated Guide to Defective Medicinal Products, signalling a refreshed emphasis on rapid defect detection, structured investigations, and decisive recall process.

In Australia, the Therapeutic Goods Administration (TGA) continues to enforce its expectations under the Procedure for recalls, product alerts and product corrections (PRAC), (replacing the URTPG in March 2025) which has refocussed their expectations on sponsor and manufacturer responsibilities for recall process and decisions.

These developments arrive at a time when the global supply chain is increasingly complex and at risk, product lifecycles are accelerating, and organisations face growing expectations for transparency and traceability. For manufacturers, sponsors, and distributors, the message is clear: recall‑ready systems are no longer optional—they are fundamental to Good Manufacturing Practice (GMP) compliance and patient safety.

Overview of the 2026 UK Guide to Defective Medicinal Products

The updated MHRA guide (February 2026) provides updated expectations for identifying, reporting, investigating, and managing suspected defective medicines. It applies to licensed and unlicensed medicinal products, including specials and imported unlicensed medicines, as well as substances used in their manufacture or packaging.

The MHRA guide formalises how defects must be managed in practice. Licence holders must submit defect notifications via the MHRA Defective Medicines Online Reporting Form, apply MedDRA terminology when classifying defects, and immediately notify the Defective Medicines Report Centre (DMRC) by telephone for critical or major defects. The MHRA is explicitly discourages waiting for internal investigations to conclude before making contact with them.

The guide applies to:

• Manufacturers and marketing authorisation holders (MAHs)
• Wholesalers and distributors
• Healthcare professionals and patients (regarding reporting routes)

Key messages for manufacturers and sponsors

• Early detection is vital – Signals from complaints, deviations, out‑of‑specification (OOS) results, and stability failures must feed quickly into defect evaluation.
• Timely and risk‑based decisions – The guide reinforces the need for rapid triage based on patient impact and defect severity.
• Structured investigations – Organisations must demonstrate a clear, reproducible investigation approach aligned with GMP and consistent with ICH Q9 (Quality Risk Management).
• Robust communication pathways – Expectations cover communication with regulators, healthcare professionals, distributors, and sometimes patients.

The guide complements, rather than replaces, existing GMP frameworks, and its message mirrors what Australian and EU regulators have been signalling: defect management must be structured, data‑driven, and decisively governed.

How UK expectations compare with TGA PRAC, FDA recall process, and EU standards

Across jurisdictions, regulatory language differs, but the underlying expectations show notable alignment.

Common global themes

Risk classification

• UK (MHRA): Defect Classes 1–4, based on patient risk and clinical impact
• Australia (TGA): Recall Classes I, II, and III
• United States (FDA): Recall Classes I, II, and III
• European Union (EMA): Critical, major or minor defect risk classification

Timelines

All regulators expect rapid escalation and well‑documented decision‑making, often requiring immediate notification for high‑risk defects.

Communication expectations

Whether MHRA, TGA, FDA, or EMA, the principles are similar:

• Clear, accurate, and timely messaging
• Defined responsibilities for sponsors and manufacturers
• Assurance that communications reach the intended audience

In practice, multinational organisations benefit from harmonised internal frameworks, ensuring that global expectations can be met without reinventing processes for each regulator.

Designing a structured defect triage and investigation process for recalls

A well‑designed defect handling process follows a logical flow.

Integrating complaints, deviations, and stability failures into defect evaluation

Many organisations struggle because defect‑related data lives in multiple systems—complaints databases, deviation logs, CAPA systems, and stability management systems.

A recall‑ready QMS integrates these streams so that:

• Trends become visible instead of buried in data silos
• Signal detection is proactive, not reactive
• Investigations are better informed, reducing rework and recall delays

A practical approach is to implement periodic cross‑functional defect review meetings. These ensure ongoing alignment between QA, QC, manufacturing, regulatory, and supply chain.

For broader context on integrating continuous improvement into GMP systems, see the approach outlined in PharmOut’s Continuous Improvement blog.

Building an effective recall decision‑making framework and governance

Clear governance structures prevent delay and inconsistency. Effective recall governance includes defined escalation criteria, delegated decision authority, access to cross‑functional expertise, and visible senior management involvement for high‑risk defects.

The MHRA considers notifications to the regulator only after a recall has commenced as non‑compliant. Where uncertainty exists, consult early with the DMRC.

Key roles

• QA (Quality Assurance): Coordinates defect assessment, manages investigations, and liaises with regulators.
• RP/QP (Responsible Person / Qualified Person): Ensures regulatory compliance and product release considerations are factored into decisions.
• Senior management: Must be visibly involved for high‑risk defects, providing authority and resources.

What good governance looks like

• Pre‑defined escalation criteria
• Delegated authorities for urgent decision‑making
• Availability of experts across quality, manufacturing, medical, and regulatory affairs
• Documentation that clearly justifies decisions and timelines

This structure ensures decisions are consistent, defendable, and timely.

Communication plans: regulators, health professionals, patients, media

Communication delays are a recurring cause of regulatory non‑compliance. To avoid this finding, organisations should maintain:

• Pre‑approved templates for recall notices and stakeholder communications
• Escalation trees identifying who contacts whom, when, and how
• Multichannel communication strategies, including:
  • Healthcare professional letters
  • Distributor notifications
  • Website statements
  • Social media (where appropriate and compliant)
  • Direct-to-patient notifications (when required)

Clear communication reduces confusion, protects patients, and demonstrates organisational maturity.

Testing your recall system: mock recalls and performance metrics

A recall system is only as good as its execution. Regulators frequently expect evidence that recall processes have been tested.

Mock recalls

These exercises validate real‑world performance, reveal bottlenecks, and strengthen team readiness. Conduct them annually or more often for high‑risk product categories.

Metrics to track

• Traceability success rate: Percentage of product accounted for
• Contact success rate: How effectively the organisation reaches distributors or customers
• Recall cycle time: Duration between defect identification and action completion
• Effectiveness check performance: Accuracy of confirmation activities
• Documentation completeness: Evidence of actions and decisions

Good metrics support continuous improvement and help demonstrate compliance during inspections.

Practical tips

Repeated inspection findings include:

• Slow escalation because defect classification criteria were unclear
• Poor documentation of investigation rationale
• Lack of integration between complaints, deviations, and stability data
• Delayed communication with regulators or healthcare professionals
• Inadequate mock recall evidence

But employing practical fixes will help you overcome these issues:

• Develop decision trees that support consistent classification
• Use standardised investigation templates to ensure completeness
• Hold monthly defect review meetings to break down data silos
• Maintain up‑to‑date regulator contact lists
• Run cross‑functional mock recalls involving QA, supply chain, medical, and regulatory teams

These small but high‑impact improvements significantly increase organisational readiness.

Conclusion

In 2026, defective medicine management and recall governance are increasingly viewed as indicators of overall quality system maturity and the regulatory landscape for defect management and recalls is accelerating, not slowing. With the updated UK guidance, ongoing TGA focus, and global alignment across FDA and EU regulators, organisations must ensure their systems are proactive, integrated, and well governed.

A recall‑ready quality system not only protects patients but also strengthens regulatory confidence and operational resilience. Investing now in well‑structured processes, informed governance, and regular testing ensures that when defects occur, your organisation responds swiftly, confidently, and compliantly.

PharmOut Services & Training

PharmOut supports pharmaceutical manufacturers, sponsors, and supply chain partners in buildingrecall‑ready GMP quality systems aligned with global regulatory expectations. Our consultants assist with complaint handling and defect triage, investigation frameworks, recall governance, and mock recall execution to strengthen inspection readiness and patient safety.
PharmOut also delivers targeted training in defective product management, risk‑based investigations, and recall preparedness through tailored in‑house workshops, public courses, and eLearning.
Explore elearning and public courses via onlinegmptraining.com, or contact us via the website or via email to tailor workshops to your needs.

Frequently Asked Questions (FAQ)